Evidence map›Paper›PMID 39582538›Full record

ArticleFrontiers in oncology2024

Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data.

Li-Rong Yang, Mei Yang, Liu-Lin Chen, Yong-Lin Shen, Yuan He, Zong-Ting Meng, Wan-Qi Wang, Feng Li, Zhi-Jin Liu, Lin-Hui Li and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Li-Rong Yang *Hematology Oncology Department, the Southern Central Hospital of Yunnan Province, Honghe, Yunnan, China.
Mei Yang *Geriatric Oncology Department, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Liu-Lin ChenHematology Oncology Department, the Southern Central Hospital of Yunnan Province, Honghe, Yunnan, China.
Yong-Lin ShenHematology Oncology Department, the Southern Central Hospital of Yunnan Province, Honghe, Yunnan, China.
Yuan HeGeriatric Oncology Department, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Zong-Ting MengGeriatric Oncology Department, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Wan-Qi WangGeriatric Oncology Department, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Feng LiDepartment of Oncology, the Pingxiang People's Hospital, Pingxiang, Jiangxi, China.
Zhi-Jin LiuDepartment of Oncology, The First Hospital of Nanchang, Nangchang, Jiangxi, China.
Lin-Hui LiHematology Oncology Department, the Southern Central Hospital of Yunnan Province, Honghe, Yunnan, China.
Yu-Feng WangGeriatric Oncology Department, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xin-Lei LuoDepartment of Spinal Surgery, Southern Central Hospital of Yunnan Province, Honghe, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Most epithelial ovarian cancer (EOC) eventually develops recurrence. Identification of high-risk patients can prompt earlier intervention and improve long-term outcomes. We used laboratory and clinical data to create models based on machine learning for EOC platinum resistance recurrence identification. Methods: This study was designed as a retrospective cohort analysis. Initially, we identified 1,392 patients diagnosed with epithelial ovarian cancer who underwent platinum-based chemotherapy at Yunnan Cancer Hospital between January 1, 2012, and June 30, 2022. We collected data on the patients' clinicopathologic characteristics, routine laboratory results, surgical information, details of chemotherapy regimens, and survival outcomes. Subsequently, to identify relevant variables influencing the recurrence of platinum resistance, we screened thirty potential factors using two distinct variable selection methods: Lasso regression and multiple logistic regression analysis. Following this screening process, five machine learning algorithms were employed to develop predictive models based on the selected variables. These included decision tree analysis (DTA), K-Nearest neighbor (KNN), support vector machine (SVM), random forest (RF), and eXtreme gradient boosting (XGBoost). The performance of these models was compared against that of traditional logistic regression. To ensure robust internal validation and facilitate comparison among model performance metrics, a five-fold cross-validation method was implemented. Key performance indicators for the models included the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and average accuracy. Finally, we will visualize these models through nomograms, decision tree diagrams, variable importance plots, etc., to assist clinicians in their practice. Results: Multiple logistic regression analysis identified eight variables associated with platinum resistance recurrence. In the lasso regression, seven variables were selected. Based on the findings from both Lasso regression and multiple logistic regression analysis, models were developed using these 7 and 8 factors. Among these, the XGBoost model derived from multiple logistic regression exhibited superior performance and demonstrated good discrimination during internal validation, achieving an AUC of 0.784, a sensitivity of 0.735, a specificity of 0.713, an average accuracy of 80.4%, with a cut-off value set at 0.240. Conversely, the LR model based on lasso regression yielded commendable results as well; it achieved an AUC of 0.738, a sensitivity of 0.541, a specificity of 0.836, with a cut-off value established at 0.154 and an accuracy rate of 79.6%. Finally, we visualized both models through nomograms to illustrate the significance of each variable involved in their development. Conclusions: We have successfully developed predictive models for platinum-resistant recurrence of epithelial ovarian cancer, utilizing routine clinical and laboratory data. Among these models, the XGBoost model-derived from variables selected through multiple logistic regression-demonstrated the best performance. It exhibited high AUC values and average accuracy during internal validation, making it a recommended tool for clinical use. However, due to variations in time and context, influencing factors may change over time; thus, continuous evolution of the model is necessary. We propose a framework for this ongoing model adaptation.

Indexed as

early detection of cancermodelnomogramplatinum resistancerecurrence

Identifiers

PMID39582538
PMCPMC11581972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.